Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Frequently asked questions
What sector does Genelux Corporation Common Stock (GNLX) operate in?
Genelux Corporation Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Genelux Corporation Common Stock (GNLX) current stock price?
As of the latest data, Genelux Corporation Common Stock stock price is $1.89, with a previous close of $1.91. Genelux Corporation Common Stock lost -$0.02 in the last trading session, representing a -1.05% loss.
What is Genelux Corporation Common Stock (GNLX) current market capitalization?
Genelux Corporation Common Stock market cap is approximately 85.51 million.
What is Genelux Corporation Common Stock (GNLX) Earnings Per Share (EPS)?
The trailing EPS is -$0.86, and the forward EPS is -$0.75.
What is Genelux Corporation Common Stock (GNLX) EBITDA?
Genelux Corporation Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -9.46 million.
Does Genelux Corporation Common Stock (GNLX) pay dividends?
No. Genelux Corporation Common Stock does not pay a dividend.
When is Genelux Corporation Common Stock (GNLX) next earnings report?
Genelux Corporation Common Stock is expected to release its next earnings report on September 30, 2026.
What is Genelux Corporation Common Stock (GNLX) beta (volatility) score?
Genelux Corporation Common Stock has a beta of 0.557, indicating lower volatility than the overall market.
